Skip to main content
Premium Trial:

Request an Annual Quote

Cota Raises $40M in Series C Round

NEW YORK (GenomeWeb) – Healthcare data analytics company Cota announced today that it has closed a $40 million Series C round of financing.

The round was led by Iqvia with participation from EW Healthcare Partners and Memorial Sloan Kettering Cancer Center, as well as existing investors Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health, and Atoc Holdings. In connection with the transaction, Iqvia has received a seat on Cota's board.

The company said it would use the funding to advance its Cota Nodal Address classification system — which creates patient cohorts by categorizing patient-specific medical histories, information on their diseases, and planned therapies — and to scale up its other real-world evidence and analytics platforms geared toward healthcare providers, payors, and life science companies.

Earlier this year, Cota was selected to help develop precision medicine and research programs at the Miami Cancer Institute. And in late 2017, the firm partnered with Memorial Sloan Kettering Cancer Center to build clinical and genomic data sets for personalized medicine. In 2016, Cota began collaborating with Guardant Health to study barriers to genomic profiling in lung cancer patients.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.